Internet Advertising

 

weight loss phentermine

Life Insurance



Search:


Search: weight loss phentermine
Open Directory Categories (1-1 of 1)
  1. Health: Pharmacy: Drugs and Medications: P: Phentermine   (1 match)

Open Directory Sites (1-1 of 1)

  1. Phentermine for Weight Loss - A consumer guide about taking Phentermine for weight loss. Learn how the drug is used, the dangers and the side effects.
    -- http://www.healthyweightforum.org/eng/articles/phentermine   Health: Pharmacy: Drugs and Medications: P: Phentermine   (1)

Help build the largest human-edited directory on the web.
Submit a Site - Open Directory Project - Become an Editor

The content of this directory is based on the Open Directory and may have been modified by DWodp

make_money - beautiful naked women - sexy nude women - french women - xxx women - bordeaux wine - wine cooler - wine tours - acupuncture weight loss - medical weight loss clinic - weight loss exercises - nicole richie weight loss - 50th wedding anniversary - wedding consultant - wedding registry - wedding halls - adult website traffic - adult website traffic - website traffic analysis - free traffic to website - check website traffic - adult web hosting - free web server - web domain hosting - web server software - affordable web design - how to design a web page - web design hosting - website design awards -

Yahoo! News Search Results for weight loss phentermine
01/01/2009 04:54 AM
Medical board disciplines 59 doctors and issues 479 physician licenses (Cleveland Advocate)
Since its last board meeting, the Texas Medical Board took disciplinary action against 59 licensed physicians.
12/23/2008 07:56 PM
Weight-Loss Potions Have Hidden Surprises (US News & World Report)
The FDA is concerned that people are taking powerful diet drugs with no knowledge of dose or effect.
12/24/2008 12:03 PM
Diet pills recalled for possible health risks. (Orange County Register)
25 weight loss products contain ingredients FDA says might pose health risks.
12/15/2008 01:12 PM
Qnexa Meets Primary Endpoint By Demonstrating Superior Weight Loss Over Components And Placebo In The 28-Week Equate ... (Medical News Today)
VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced positive results from the EQUATE study (OB-301), a 28-week, phase 3 obesity trial conducted at 32 sites with Qnexaâ„¢, an investigational drug.
12/18/2008 07:04 PM
Texas Medical Board disciplines 57 doctors (Fort Worth Star-Telegram)
Texas Medical Board acts for a variety of reasons against physicians.
12/18/2008 07:13 PM
The 57 disciplined doctors (Fort Worth Star-Telegram)
BY ALEX BRANCH In recent weeks, the Texas Medical Board has taken disciplinary action against 57 licensed physicians and issued a cease and desist order against an unlicensed Austin woman. Here are details: QUALITY OF CARE VIOLATIONS Abou-Sleiman, Joseph E., Lic. No. L9593, Houston, TX On December 12, 2008, the Board and Dr. Abou-Sleiman entered into an Agreed Order requiring that, within ...
12/18/2008 06:11 PM
The Texas Medical Board Disciplines 57 Doctors (KLTV 7 Tyler)
Since its last board meeting, the Texas Medical Board took disciplinary action against 57 licensed physicians. The actions included 13 violations based on quality of care; two actions based on unprofessional
12/18/2008 07:09 PM
Medical board disciplines 57 doctors and issues 479 physician licenses (Cleveland Advocate)
Medical Board Disciplines 57 Doctors and Issues 479 Physician Licenses
12/11/2008 10:27 AM
Qnexa Meets Primary Endpoint by Demonstrating Superior Weight Loss over Components and Placebo in the 28-Week Equate ... (Centre Daily Times)
VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced positive results from the EQUATE study (OB-301), a 28-week, phase 3 obesity trial conducted at 32 sites with Qnexaâ„¢, an investigational drug. The EQUATE study met the primary endpoint by demonstrating superior weight loss with both the full-dose ...
12/16/2008 09:13 AM
Qnexa Reduces Hemoglobin A1c By 1.6% In 56 Weeks (Medical News Today)
VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced positive results from the DM-230 study, a 56-week, randomized, double-blind, placebo-controlled, efficacy and safety study of Qnexaâ„¢, an investigational drug, for the glycemic management of obese type 2 diabetics.